← Eichor
Study identifier: NCT06938360 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Clinical Efficacy and Safety Assessment of Breast-Conserving Surgery for Central Breast Cancer: A Prospective Randomized Controlled Trial

Condition: Breast Cancer  ·  Sponsor: Xijing Hospital

PhaseNA
Planned participants158
Who can joinFemale, 18 Years to 70 Years
Healthy volunteersNo

About this study

This study enrolled 158 patients with primary central early-stage breast cancer and randomly assigned them to two groups. The control group underwent total mastectomy (with optional prosthetic implantation or autologous tissue reconstruction), while the experimental group received breast-conserving surgery combined with radiotherapy (nipple resection with concurrent nipple reconstruction and oncoplastic surgery when nipple involvement was present; conversion to total mastectomy required for intraoperative or postoperative positive margins). The primary endpoint was local recurrence rate, with secondary endpoints including disease-free survival (DFS), overall survival (OS), patient-reported outcomes (PRO), and surgery-related complications.

This description comes directly from the study's public registry record.

Talk to the study team

Ju liang J L Zhang  ·  029-84775271  ·  vascularzhang@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Xijing hospitalXi'an, Shaanxi, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06938360